Investigator-sponsored study funded by Glaucoma UK and the HSC R&D Division expands ART27.13’s clinical potential into ophthalmologyFirst ...

Please provide your email address to receive an email when new articles are posted on . I was honored to give the Stephen A. Obstbaum, MD, Lecture at the 2022 American Society of Cataract and ...

Please provide your email address to receive an email when new articles are posted on . Primary care optometrists play a critical role in screening for and diagnosing glaucoma, leading to earlier ...

Artelo Biosciences (NASDAQ:ARTL) is expanding its development pipeline into ophthalmology with a new clinical study evaluating its drug candidate ART27.13 for the treatment of glaucoma. The San ...

Glaucoma, caused by high pressure within the eye, affects some 2.5 million Americans and is the nation's second leading cause of blindness. Optometrists screen for it during routine eye exams, often ...

Glaucoma is a devastating eye disease that currently affects more than 3 million Americans. By the year 2050, data shows the number of cases is projected to surge to more than 6 million cases. This is ...

Communicating to patients that they need to come to their annual checkup is important for eye doctors to convey to help treat their patients, says Ariana Levin, MD. Glaucoma is a disease that affects ...

Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial ...

Markers in the blood that predict whether glaucoma patients are at higher risk of continued loss of vision following conventional treatment have been identified by researchers. Markers in the blood ...

As the elderly population grows, the number of glaucoma patients continues to rise. However, there is also a notable increase in glaucoma cases among younger individuals in their 20s to 40s, ...

Patients with endogenous Cushing syndrome (CS) have a higher risk for glaucoma than the general population, with the clinical manifestations appearing at a younger age. The risk persisted regardless ...